Category: hypoactive sexual desire dysfunction HSDD
Share your opinions as a woman with POI/ Premature menopause.
International POI guideline update survey What matters for you? A 10 minute scoping survey for women or for health professionals: An international collaboration between the European… Continue Reading →
IMS: Sexual wellbeing after menopause
Free yourself and embrace positive sexual wellbeing Sexual health is a state of physical, emotional, mental and social wellbeing related to sexuality. After menopause… Continue Reading →
Perimenopause Online Event : May 3-4 2022
Get Your Tickets Here. Finally, Help Has Arrived. Expert advice, from the people who really know perimenopause. Streaming online and includes on-demand access: May 3-4 2022… Continue Reading →
AndroFeme 1 included on ARTG for hypoactive sexual desire dysfunction in postmenopausal women
Lawley Pharmaceuticals’ female-specific hormone cream, AndroFeme® 1, has been registered on the Australian Register of Therapeutic Goods (ARTG) for the treatment of postmenopausal women… Continue Reading →
AndroFeme 1 licensed for hypoactive sexual desire dysfunction in postmenopausal women
Lawley Pharmaceuticals has obtained approval for registration of AndroFeme® 1 in the Australian Register of Therapeutic Goods (ARTG) for the treatment of postmenopausal women… Continue Reading →
Tanner Pharma Group and Lawley Pharmaceuticals Initiate Global Named Patient Program for AndroFeme® 1
Friday 12th June 2020 Perth, Australia and Charlotte, USA – Lawley Pharmaceuticals and Tanner Pharma Group announced today that they have initiated a global… Continue Reading →
Tanner Pharma Group and Lawley Pharmaceuticals Initiate Global Named Patient Program for AndroFeme® 1
Friday 12th June 2020 Perth, Australia and Charlotte, USA – Lawley Pharmaceuticals and Tanner Pharma Group announced today that they have initiated a global… Continue Reading →
TGA accepts AndroFeme 1 for evaluation in postmenopausal women with Hypoactive Sexual Desire Dysfunction.
TGA accepts AndroFeme 1 for evaluation in postmenopausal women with HSDD. Perth, Western Australia; Dec. 05, 2019 — Lawley Pharmaceuticals today announced AndroFeme 1,… Continue Reading →
TGA accepts Lawley product for evaluation in postmenopausal women with HSDD.
TGA accepts Lawley product for evaluation in postmenopausal women with HSDD. Perth, Western Australia; Dec. 05, 2019 — Lawley Pharmaceuticals Pty Ltd today announced… Continue Reading →
Global Consensus Position Statement on the Use of Testosterone Therapy for Women
The Global Consensus Position Statement on the Use of Testosterone Therapy for Women was simultaneously published on the 2nd September 2019 in Maturitas, Journal… Continue Reading →